KeyCorp Trims Charles River Laboratories International (NYSE:CRL) Target Price to $300.00

Charles River Laboratories International (NYSE:CRLGet Rating) had its target price lowered by analysts at KeyCorp from $390.00 to $300.00 in a report issued on Thursday, The Fly reports. KeyCorp’s target price suggests a potential upside of 16.50% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. UBS Group cut their price target on shares of Charles River Laboratories International from $465.00 to $420.00 and set a “buy” rating for the company in a report on Thursday, February 17th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Charles River Laboratories International from $409.00 to $350.00 and set a “buy” rating for the company in a report on Thursday, February 17th. StockNews.com began coverage on shares of Charles River Laboratories International in a report on Thursday, March 31st. They issued a “hold” rating for the company. Jefferies Financial Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating and cut their price target for the company from $370.00 to $280.00 in a report on Monday, April 25th. Finally, Wells Fargo & Company decreased their price target on shares of Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating on the stock in a research note on Monday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $387.88.

Shares of NYSE:CRL opened at $257.51 on Thursday. The stock has a market cap of $13.00 billion, a P/E ratio of 33.88, a P/E/G ratio of 1.51 and a beta of 1.27. The firm has a fifty day moving average price of $276.58 and a 200 day moving average price of $331.73. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.23 and a quick ratio of 1.04. Charles River Laboratories International has a 1-year low of $230.62 and a 1-year high of $460.21.

Charles River Laboratories International (NYSE:CRLGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The medical research company reported $2.75 EPS for the quarter, topping the Zacks’ consensus estimate of $2.72 by $0.03. The company had revenue of $913.93 million during the quarter, compared to the consensus estimate of $908.64 million. Charles River Laboratories International had a net margin of 11.04% and a return on equity of 22.38%. Charles River Laboratories International’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.53 EPS. Sell-side analysts expect that Charles River Laboratories International will post 11.63 EPS for the current fiscal year.

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 396 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $290.83, for a total transaction of $115,168.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO James C. Foster sold 17,436 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $288.67, for a total transaction of $5,033,250.12. The disclosure for this sale can be found here. Insiders sold 38,975 shares of company stock worth $11,791,146 over the last three months. Corporate insiders own 1.10% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Wills Financial Group Inc. raised its stake in shares of Charles River Laboratories International by 1.1% during the third quarter. Wills Financial Group Inc. now owns 2,467 shares of the medical research company’s stock valued at $1,018,000 after purchasing an additional 26 shares during the period. Creative Planning raised its stake in shares of Charles River Laboratories International by 1.4% during the third quarter. Creative Planning now owns 2,234 shares of the medical research company’s stock valued at $922,000 after purchasing an additional 30 shares during the period. Argent Trust Co raised its stake in shares of Charles River Laboratories International by 2.4% during the fourth quarter. Argent Trust Co now owns 1,266 shares of the medical research company’s stock valued at $477,000 after purchasing an additional 30 shares during the period. Shaker Investments LLC OH raised its stake in shares of Charles River Laboratories International by 0.7% during the third quarter. Shaker Investments LLC OH now owns 5,100 shares of the medical research company’s stock valued at $2,105,000 after purchasing an additional 33 shares during the period. Finally, Intrust Bank NA raised its stake in shares of Charles River Laboratories International by 1.1% during the fourth quarter. Intrust Bank NA now owns 3,146 shares of the medical research company’s stock valued at $1,185,000 after purchasing an additional 33 shares during the period. 93.06% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

The Fly logo

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.